From Yahoo Finance.: 2025-06-13 14:10:00

Insmed Incorporated (NASDAQ: INSM) is one of the 10 Best Growth Stocks Under $100 to Buy Now. The success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP), led to a 32% surge in shares over five days. Discussions with the FDA for Phase 3 trials roadmap are underway. The global PAH market is projected to reach $12.2 billion by 2032.

Insmed Incorporated (NASDAQ: INSM) has submitted its New Drug Application (NDA) for brensocatib to treat Non-cystic fibrosis bronchiectasis (NCFBE) patients, with a review date set for August 12, 2025. The company is positioned for high growth potential with the upcoming phase 3 studies. Insmed focuses on developing therapies for serious and rare diseases globally.

Insmed Incorporated (NASDAQ: INSM) is a New Jersey-based biopharmaceutical company dedicated to creating life-changing therapies for patients with rare and serious diseases. The company’s recent successes in developing treatments for PAH and NCFBE highlight its commitment to innovation and patient care.

While Insmed (INSM) shows promise as an investment, other AI stocks may offer greater potential with lower risks. For those seeking undervalued AI stocks with significant growth potential, exploring alternative options may be beneficial. Stay informed on market trends and opportunities to maximize investment returns.



Read more at Yahoo Finance.: Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results